Daniel Bustos
Hospital Italiano de Buenos Aires
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daniel Bustos.
Transplantation | 2000
Jorge R. Ferraris; Monica L. Tambutti; Mar A. Redal; Daniel Bustos; Jos A. Ramirez; Norma Prigoshin
BACKGROUND Chronic rejection is the leading cause of graft failure. Both nonimmunological and immunological mechanisms contribute to this pathology. METHODS We studied changes in kidney function, mixed lymphocyte culture, cell-mediated lympholysis, serum HLA class I antigens, cytotoxic antibodies, and lymphocyte population before and after 6 months of follow-up in 22 pediatric renal transplanted patients. The immunosuppressive protocol used was: cyclosporine, azathioprine, and corticosteroids. Eight patients demonstrated chronic graft rejection (by biopsy), group I; and eight patients had no clinical evidence of chronic and/or acute rejection, group II. Substitution of mycophenolate mofetil (MMF) (600 mg/m2 bid for azathioprine was done in patients of groups I and II. Another six patients with chronic rejection, did not receive MMF, group III. RESULTS Creatinine clearance increased in group I (44+/-5 vs. 51.1+/- ml/min/1.73 m2, P<0.03) but it decreased in group III (30+/-3 vs. 25+/-2, P<0.01). Urinary protein excretion decreased only in group I (0.3+/-0.03 to 0.06+/-0.03 g/24 hr, P<0.03). During MMF therapy antidonor mixed lymphocyte culture decreased 62 and 70% (P<0.05) in group I and II. Cell-mediated lympholysis against lymphocyte of the donor decreased 65% (P<0.05) in group I. Cell-mediated lympholysis toward control cells decreased 54% (P<0.01) in group II. Serum HLA class I antigens, only decreased from 0.7+/-0.1 to 0.5+/-0.1 microl/ml, P<0.05, in group I. CD19+ decreased from 7.9+/-1.1 to 5.6+/-0.8%, P<0.05, and 7.8+/-1.2 to 5.5+/-0.9%, P<0.05, in groups I and II, respectively. CD16+ increased from 5.7+/-1.1 to 8.6+/-1.3 (P<0.05) only in group I. CONCLUSIONS Our data suggest that substituting MMF for azathioprine therapy leads to an improvement in the immunosuppression and renal function in children with on-going chronic rejection.
American Journal of Reproductive Immunology | 2006
Daniel Bustos; Ana Moret; Monica L. Tambutti; S Gogorza; Roberto Testa; Amanda Ascione; Norma Prigoshin
To determine the presence or absence of subclinical autoimmunity in Caucasian Argentine healthy women with first trimester recurrent pregnancy loss (RPL), the sera of 118 healthy women with a history of three or more consecutive abortions and 125 fertile control women without abortions and two children were analyzed for the presence of autoantibodies: immunoglobulin (Ig)G and IgM anticardiolipin, antinuclear (ANA), antismooth muscle (ASMA), antimitocondrial (AMA), antiliver‐kidney‐microsomal fraction (LKM), antigastric parietal cells (GPC), antineutrophil cytoplasmatic (ANCA) and antibodies antigliadin type IgA and IgG and IgA antitransglutaminase related with celiac disease (CD).
Glycobiology | 2002
Pablo Argibay; Javier M. Di Noia; Alejandra Hidalgo; Esteban Mocetti; Mariana Barbich; Alicia Lorenti; Daniel Bustos; Monica L. Tambutti; Sung H. Hyon; Alberto C.C. Frasch; Daniel O. Sánchez
Acta Bioquimica Clinica Latinoamericana | 2007
Mirta Beatriz Caracciolo; Sandra Muzietti; Marcela Pandolfo; Gustavo Negri; Daniel Bustos
Archive | 2012
Beatriz Caracciolo; Sandra Muzietti; Marcela Pandolfo; Gustavo Negri; Daniel Mazziotta; Daniel Bustos
Archive | 2012
Beatriz Caracciolo; Sandra Muzietti; Marcela Pandolfo; Gustavo Negri; Daniel Mazziotta; Daniel Bustos
Acta Bioquimica Clinica Latinoamericana | 2012
Beatriz Caracciolo; Sandra Muzietti; Marcela Pandolfo; Gustavo Negri; Daniel Mazziotta; Daniel Bustos
Archive | 2007
Mirta Beatriz Caracciolo; Sandra Muzietti; Marcela Pandolfo; Gustavo Negri; Daniel Bustos
Rev. argent. transfus | 2004
Daniel Bustos; Marcos Andres Bujas; Amanda Ascione
Acta Bioquimica Clinica Latinoamericana | 2003
Ana Moret; María Paula Saporiti; Amanda Ascione; Daniel Bustos